CCG-1423 MedChemExpress (MCE)

Product Name	CCG-1423
Synonyms	CCG-1423 CCG 1423 N-(2-(4-Chloroanilino)-1-Methyl-2-oxoethoxy)-3,5-bis(trifluoroMethyl)benzaMide N-(1-(4-chlorophenylaMino)-1-oxopropan-2-yloxy)-3,5-bis(trifluoroMethyl)benzaMide N-[2-[(4-Chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)-benzamide Synonyms CCG-1423 CCG 1423 N-(2-(4-Chloroanilino)-1-Methyl-2-oxoethoxy)-3,5-bis(trifluoroMethyl)benzaMide N-(1-(4-chlorophenylaMino)-1-oxopropan-2-yloxy)-3,5-bis(trifluoroMethyl)benzaMide N-[2-[(4-Chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)-benzamide N-({1-[(4-Chlorophenyl)Amino]-1-Oxo-2-Propanyl}Oxy)-3,5-Bis(Trifluoromethyl)Benzamide CCG-1423
CAS	285986-88-1
EINECS
Chemical Formula	C18H13ClF6N2O3
Molecular Weight	454.75
inchi
Package	10 mM * 1 mL;5 mg;10 mg;50 mg;100 mg;200 mg
Price	Email to quote
Descriptions	CCG-1423 CCG-1423 MedChemExpress (MCE) HY-13991 285986-88-1 99.94% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US Descriptions CCG-1423 CCG-1423 MedChemExpress (MCE) HY-13991 285986-88-1 99.94% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US may vary elsewhere. CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes. CCG-1423 (10 μM 24 h) affects invasion by cultured PC-3 cells into a Matrigel matrix and inhibits 54% mitochondrial metabolism of WST-1[1].?CCG-1423 (0-100 μM 24 h) inhibits RhoA and RhoC signaling pathways with an IC50 value of 1.5 μM for Rho-pathway selective serum response element-luciferase reporter[1].?CCG-1423 (1 μM 16 h) improves glucose uptake in both L6 cells and primary human myotubes[2].?CCG-1423 (10 μM 18-19 h) inhibits expression of Rho downstream[2].?CCG-1423 (3 μM 25 h) selectively stimulates apoptosis of RhoC-overexpressing melanoma cell line (A375M2) compared with the parental cell line (A375)[3]. CCG-1423 (0.15 mg/kg i.p. once daily for two weeks) affects glucose tolerance and insulin levels in HFD-fed mice[1]. IC50: 1.5 µM (Rho-pathway selective serum response element-luciferase reporter)[1] In Vitro CCG-1423 (10 μM 24 h) affects invasion by cultured PC-3 cells into a Matrigel matrix and inhibits 54% mitochondrial metabolism of WST-1[1].?CCG-1423 (0-100 μM 24 h) inhibits RhoA and RhoC signaling pathways with an IC50 value of 1.5 μM for Rho-pathway selective serum response element-luciferase reporter[1].?CCG-1423 (1 μM 16 h) improves glucose uptake in both L6 cells and primary human myotubes[2].?CCG-1423 (10 μM 18-19 h) inhibits expression of Rho downstream[2].?CCG-1423 (3 μM 25 h) selectively stimulates apoptosis of RhoC-overexpressing melanoma cell line (A375M2) compared with the parental cell line (A375)[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> CCG-1423 Related Antibodies Cell Invasion Assay[1] Cell Line: PC-3 cell line \| \| \| \| \| \| \| \| \| \| [1]. Evelyn CR, et al. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett. 2010 Jan 15 20(2):665-72. [Content Brief] [2]. Jin W, et al. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest. 2011 Mar 121(3):918-29. [Content Brief] [3]. Evelyn CR, et al. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther. 2007 Aug 6(8):2249-60. [Content Brief]
Supplier Website	https://www.medchemexpress.com/CCG-1423.html
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-04-01 14:45:47

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-04-01 14:45:47

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-04-01 14:45:47

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-04-01 14:45:47

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-04-01 14:45:47

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-04-01 14:45:47

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-04-01 14:45:47

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact